Inclusion Criteria:

- Advanced cutaneous T-cell lymphoma on or following two systemic therapies

- Female participants must have a negative serum pregnancy test within 3 days of the
first dose of vorinostat

- Female participants must have finished menopause, or are surgically sterilized, or
agree to use 2 adequate barrier methods of contraception

- Male participants must agree to use 2 adequate barrier methods of contraception

- To be treated on extension phase of study participant must have been treated on the
base study for Protocol 042

Exclusion Criteria:

- Currently receiving any potential histone deacetylase (HDAC) inhibitor (e.g. valproic
acid)

- Currently receiving any other systemic therapy for CTCL. Corticosteroids that are
similar in strength to 20 mg of prednisone daily are permitted

- Pregnant or lactating

- Known allergy to any component of the study drug

- Eligible for any other study of vorinostat in CTCL patients